In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
Kristina Zucchi is an investment analyst and financial writer with 15+ years of experience managing portfolios and conducting equity research. Gordon Scott has been an active investor and ...
TIME and Statista have named 500 companies pairing growth with environmental stewardship Methodology: How TIME and Statista Determined the World's Best Companies in Sustainable Growth 2025 It may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback